Jeffrey M. Witkin

Eli Lilly, Indianapolis, IN, United States 
"Jeffrey Witkin"
Mean distance: 17.34 (cluster 19)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Eiler WJA, Gleason SD, Smith JL, et al. (2019) A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity. Pharmacology, Biochemistry, and Behavior
Knopp KL, Simmons RMA, Guo W, et al. (2019) Modulation of TARP γ8-containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain. The Journal of Pharmacology and Experimental Therapeutics
Balcer OM, Seager MA, Gleason SD, et al. (2018) Evaluation of 5-HT receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behavioural Brain Research. 360: 270-278
Maxwell J, Gleason SD, Falcone J, et al. (2018) Effects of 5-HT Receptor Antagonists on Behaviors of Mice that Detect Drugs Used in the Treatment of Anxiety, Depression, or Schizophrenia. Behavioural Brain Research
Witkin JM, Shenvi RA, Li X, et al. (2018) Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies. Biochemical Pharmacology
Witkin JM, Smith JL, Ping X, et al. (2018) Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA receptors: Improved bioavailability enhances anticonvulsant efficacy. Neuropharmacology. 137: 332-343
Methuku KR, Li X, Cerne R, et al. (2018) An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABA receptors. Pharmacology, Biochemistry, and Behavior
Xu NZ, Ernst M, Treven M, et al. (2018) Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice. Psychopharmacology
Kato AS, Witkin JM. (2018) Protein complexes as psychiatric and neurological drug targets. Biochemical Pharmacology
Bruns RF, Mitchell SN, Wafford KA, et al. (2017) Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders. Neuropharmacology
See more...